MARKET WIRETradingView • 1d ago
Curanex Pharmaceuticals Inc Estimates – NASDAQ:CURXTradingView report covering Curanex Pharmaceuticals Inc (CURX) market action, institutional positioning, and fundamental catalysts.
Why CURX Stock surged +13.37% Today — RQD Quant Desk Flash
$5.85 +13.37% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $5.98
Curanex Pharmaceuticals Inc (CURX) carries a Roarable Rating of D- (Sell) with 37/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • RED ALERT
Cap $8.1M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on CURX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is CURX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Curanex Pharmaceuticals Inc (NASDAQ: CURX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $5.85 (+13.37% 1D, market cap $8.1M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 9/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Active quantitative signal LIQUIDITY_TAILWIND (BULLISH, conviction undefined/100) notes: undefined.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does CURX compare to TCRT and ENSC in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CURX carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, TCRT (Alaunos Therapeutics Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $8.1M) and ENSC (Ensysce Biosciences Inc.) posts a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $8.2M). Among the 5-stock peer group, CURX leads on earnings multiple (N/A) while CURX leads on capital efficiency (-35.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for CURX?
▼
Per CURX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002025942), Curanex Pharmaceuticals Inc generated $11.9M in revenue (+1061.2% YoY), -$4.2M in net income, and -$10.5M in free cash flow against $11.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $5.98 (+2.22%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (37/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.1% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • D-
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR RQD RADARRw E · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE-9.4% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CURX)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (37/100 Composite)
🔍 WHY CURX SCORES 37/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (27% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9
▲ #2 Bullish Driver: Whale & Options Positioning+9/20 pts (24% of score)
20D Institutional Volume Accumulation (±12.5% realized swing band)
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$4.88-2.5% Next Q
29
Q2 (-2Q)Grade E$4.76+0% Next Q
32
Q3 (-1Q)Grade E$4.76+22.9% Next Q
34
CurrentGrade D-$5.85-8.1% Hist 90D α
37
Trajectory: E (29) → D- (37)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a CURX Turnaround Squeeze
While CURX currently carries a cautious 37/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.74) and Max Pain ($6.14) forces dealer call-delta covering toward $14.49.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $CURX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “CURX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why CURX Stock surged +13.37% Today — RQD Quant Desk Flash
Curanex Pharmaceuticals Inc (CURX) surged +13.37% to $5.85, trading at 22% of its 52-week range ($3.58 – $13.8). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 22% of its 52-week range ($3.58 – $13.8) with RSI-14 at 55.8 (BULLISH MOMENTUM).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $5.85 (no active unusual options sweep snapshot on file).
- ▸Primary SEC / Cross-Feed Trigger: CURX Exhibits 5.70x True Net Liquidity Elasticity as Fed-TGA-RRP Prints $5,746B
Live CURX Headlines & Catalysts
MARKET WIREYahoo! Finance Canada • 1d ago
Alps Group Inc (ALPS) Seasonal Returns Chart - Yahoo FinanceYahoo! Finance Canada report covering Curanex Pharmaceuticals Inc (CURX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREhttps://www.siam.in/ • 1d ago
Curanex Pharmaceuticals (CURX) Slips 0.94% to $4.76 as Shares Drift Toward Lower Support - Price Targethttps://www.siam.in/ report covering Curanex Pharmaceuticals Inc (CURX) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingKey • 1d ago
Unusual Volume Stocks & Volume Spikes TodayTradingKey report covering Curanex Pharmaceuticals Inc (CURX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREhttps://www.siam.in/ • 1d ago
Curanex (CURX) Stock: Up +4.58%, Key Resistance at $5.27 2026-10-20 - Zigzag Correctionhttps://www.siam.in/ report covering Curanex Pharmaceuticals Inc (CURX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREhttps://www.dars.gov.et/ • 2d ago
Qfin (QFIN) Adds +1.97% to Recent Winning Streak 2026-10-27 - Point of Controlhttps://www.dars.gov.et/ report covering Curanex Pharmaceuticals Inc (CURX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREhttps://www.siam.in/ • 2d ago
MBINN Slips 0.16%: Merchants Bancorp Preferred Series C Holds at $18.87 Within a Well-Defined Range - Naked POChttps://www.siam.in/ report covering Curanex Pharmaceuticals Inc (CURX) market action, institutional positioning, and fundamental catalysts.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CURX)
- ✓Walkthrough of CURX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
CURX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -22.00%⚡ TESTING RESISTANCE
2026-11-03O $4.94H $5.85L $4.94C $5.85VOL 9.3K
RES: $6.15SUP: $4.00SMA50: $4.74SMA200: $6.15
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
CURX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth
vs. +1061.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on CURX today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for CURX. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for CURX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CURX)
Health Care Rank #551 of 1015
⚔️ TCRT vs CURX Full Matrix →
1. Head-to-Head Health Care Peer Comparison (CURX vs. TCRT, ENSC, MBRX, SNGX)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, Curanex Pharmaceuticals Inc (CURX) ranks #551 by composite RQD confidence (37/100, grade D-) and #909 by equity capitalization ($8.1M). Within this direct 5-issuer industry benchmark cohort, CURX leads on earnings valuation at N/A trailing P/E, while CURX leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. SNGX currently holds the highest overall quantitative score in the immediate peer group at 42/100 (D-) compared with CURX at 37/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| CURX
ACTIVE
Curanex Pharmaceuticals Inc | D- | 37/100 | — | — | -35.0% | +13.37% | $8.1M | Benchmark Subject |
| TCRT Alaunos Therapeutics Inc. | D- | 36/100 | — | — | -35.0% | -10.26% | $8.1M | /tcrt-vs-curx → |
| ENSC Ensysce Biosciences Inc. | E | 30/100 | — | — | -35.0% | -9.24% | $8.2M | /ensc-vs-curx → |
| MBRX Moleculin Biotech Inc. | E | 34/100 | — | — | -35.0% | +5.32% | $8.3M | /mbrx-vs-curx → |
| SNGX Soligenix Inc. | D- | 42/100 | — | — | -35.0% | +1.49% | $7.7M | /sngx-vs-curx → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2024–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0002025942 ↗In its most recent audited fiscal period (FY2025, filed 2025-12-31), Curanex Pharmaceuticals Inc (CURX) reported GAAP revenue of $11.9M (+1061.2% vs. FY2024 revenue of $1.0M ) , GAAP net income of -$4.2M, operating cash flow of -$10.5M, and free cash flow of -$10.5M (-1787.1% YoY). On the balance sheet, CURX closed FY2025 with $11.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $11.9M | -$4.2M | -$10.5M | -$10.5M | $11.6M | — |
| FY2024 (FY) | 2024-12-31 | $1.0M | -$361.5K | -$555.6K | -$555.6K | $517.9K | — |
3. CURX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs CURX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Curanex Pharmaceuticals Inc (NASDAQ: CURX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $5.85 (+13.37% 1D, market cap $8.1M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 9/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Active quantitative signal LIQUIDITY_TAILWIND (BULLISH, conviction undefined/100) notes: undefined.
How does CURX compare to TCRT and ENSC in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CURX carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, TCRT (Alaunos Therapeutics Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $8.1M) and ENSC (Ensysce Biosciences Inc.) posts a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $8.2M). Among the 5-stock peer group, CURX leads on earnings multiple (N/A) while CURX leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for CURX?
Per CURX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002025942), Curanex Pharmaceuticals Inc generated $11.9M in revenue (+1061.2% YoY), -$4.2M in net income, and -$10.5M in free cash flow against $11.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Where is CURX trading relative to its 50-day, 200-day, and 52-week technical levels?
CURX last traded at $5.85 (+13.37% on volume of 3,357 shares), positioning the stock +23.42% above its 50-day simple moving average ($4.74) and -4.88% below its 200-day simple moving average ($6.15). Across its 52-week range of $3.58 to $13.80, CURX sits at the 22.2% percentile with a 14-day RSI of 55.8 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($5.12 to $6.58).
ROARABLE RATING BRIEF • RQD 37/100 (D-)
✓ SEC XBRL & RQD VERIFIED
CURX — Curanex Pharmaceuticals Inc: What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31
1. Roarable Rating Brief: What This Means to a Prospective Investor
Curanex Pharmaceuticals Inc (CURX) earns a live Roarable RQD composite score of 37/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $5.85 (+13.37% 1D, market capitalization $8.1M).
- Fundamental Cash Engine (5/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of —.
- Whale 13F & Options Flow (9/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (8/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 1/9, and Debt/Equity of N/A.
2. Business Model, Unit Margins & SEC Financial Trajectory
Curanex Pharmaceuticals Inc (CURX) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry,.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Curanex Pharmaceuticals Inc (CURX) reported $11.9M in annual revenue (up from $1.0M in FY2024, +1061.2% YoY) and -$4.2M in GAAP net income. Over the multi-year SEC filing window from FY2024 ($1.0M revenue, -$361.5K net income) through FY2025, CURX scaled operating cash flow to -$10.5M and free cash flow to -$10.5M, backed by $11.6M in total assets against $0 in total debt.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (D- • RQD 37/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 9/20. With Fundamental Cash Engine at 5/20 and Institutional Whale Flow at 9/20, sustained execution supports upside toward the upper end of the $3.58 – $13.80 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
The only cross-market linkage in the data is the liquidity beta described above, which implies CURX may respond to changes in net liquidity conditions more than typical equities. Investors should monitor whether any such liquidity sensitivity persists given the weak r value, and should note that with a $7.7M market cap and 0% FCF yield, the company's capacity to absorb adverse financing conditions is not established by the source data.
- Key Question #1: Can CURX sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
- Key Question #2: Following FY2025 revenue of $11.9M and free cash flow of -$10.5M, how will capital allocation balance growth reinvestment against $0 in total debt?
- Key Question #3: How sensitive is CURX's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?
CURX Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Curanex Pharmaceuticals Inc (CURX) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE TradingView • 1d ago
Curanex Pharmaceuticals Inc Estimates – NASDAQ:CURX TradingView report covering Curanex Pharmaceuticals Inc (CURX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago
Alps Group Inc (ALPS) Seasonal Returns Chart - Yahoo Finance Yahoo! Finance Canada report covering Curanex Pharmaceuticals Inc (CURX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE https://www.siam.in/ • 1d ago
Curanex Pharmaceuticals (CURX) Slips 0.94% to $4.76 as Shares Drift Toward Lower Support - Price Target https://www.siam.in/ report covering Curanex Pharmaceuticals Inc (CURX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingKey • 1d ago
Unusual Volume Stocks & Volume Spikes Today TradingKey report covering Curanex Pharmaceuticals Inc (CURX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE https://www.siam.in/ • 1d ago
Curanex (CURX) Stock: Up +4.58%, Key Resistance at $5.27 2026-10-20 - Zigzag Correction https://www.siam.in/ report covering Curanex Pharmaceuticals Inc (CURX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE https://www.dars.gov.et/ • 2d ago
Qfin (QFIN) Adds +1.97% to Recent Winning Streak 2026-10-27 - Point of Control https://www.dars.gov.et/ report covering Curanex Pharmaceuticals Inc (CURX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE https://www.siam.in/ • 2d ago
MBINN Slips 0.16%: Merchants Bancorp Preferred Series C Holds at $18.87 Within a Well-Defined Range - Naked POC https://www.siam.in/ report covering Curanex Pharmaceuticals Inc (CURX) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
CURX Bull vs. Bear Conversation Board — What's Your Call at $5.85?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CURX 🐻 33% BEARISH CONVICTION
TA TapeReader_Pro RQD DEBATE OPENER • Price Action & Volume Trader 🐂 BULLISH
🎯 Target: $6.09 (+18.0%)
📌 Pinned Debate The Butterfly liquidity signal assigns a BULLISH 5.70x Net Liquidity beta with a MACRO TAILWIND SCORE of 96/100, though its r = -0.24 c
Here is why I am bullish on CURX here at $5.16: The Butterfly liquidity signal assigns a BULLISH 5.70x Net Liquidity beta with a MACRO TAILWIND SCORE of 96/100, though its r = -0.24 correlation is weak.. Compare CURX's 0.0% operating margin and -35.0% ROIC against the rest of Biotechnology: Pharmaceutical Preparations. As long as cash conversion holds up, dips toward $4.90 are getting bought.
SectorRotator 🐂 BULL
@ShortSeller_Dan Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.
SH ShortSeller_Dan RQD DEBATE OPENER • Forensic Short Bias 🐻 BEARISH
🎯 Target: $4.18 (-19.0%)
Spot @ $5.16 CURX scores 34/100 (grade E) with -35% ROIC, 0% FCF yield, -$10.5M FY 2025 free cash flow, and Piotroski F-Score 1/9.
Careful chasing CURX at $5.16. CURX scores 34/100 (grade E) with -35% ROIC, 0% FCF yield, -$10.5M FY 2025 free cash flow, and Piotroski F-Score 1/9.. Gross margin is 0.0%, but operating margin is 0.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $4.18 on multiple compression.